Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.82 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.90 +10.1% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.82 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.90 +10.1% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0%
Other Routine +

Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property

Red Light Holland Validates Filament Acquisition with Cocaine Trial Data, Yet Dilution Risks Loom

By The Northwire Desk — AI Analysis May 08, 2026 · 07:31 TRIP · 0.04 Red Light Holland Corp.
Executive Summary
  • Peer-reviewed randomized clinical trial published in JAMA Network Open demonstrates a single dose of psilocybin significantly reduces cocaine use over six months.
  • Red Light Holland's subsidiary Filament Health holds exclusive worldwide license to this dataset and associated intellectual property (IP).
  • Findings are intended to accelerate regulatory and clinical development for PEX010, which already has Phase 2 authorization from FDA and Health Canada.
  • Study utilized synthetic psilocybin; licensed data informs development of PEX010, a botanical-derived drug candidate.
  • Lead investigator Dr. Peter S. Hendricks notes findings are promising but preliminary, requiring adequately powered confirmatory trials.
Material Impact
  • Validation of Acquisition: The publication validates the strategic rationale behind the April 2026 acquisition of Filament Health, confirming clinical utility for a high-value indication (cocaine use disorder) beyond depression/cancer.
  • Priced-In Expectations: The stock rallied from $0.01 to $0.04 following the M&A announcement in March/April 2026; this news serves as incremental confirmation rather than a fundamental valuation shift.
  • Clinical Caveats: Management and investigators explicitly label data as "preliminary" with a need for confirmatory trials, limiting immediate commercial impact compared to regulatory approval milestones.
  • Dilution Context: The acquisition involved issuing ~182 million shares (30% of combined entity), significantly diluting existing shareholders; this news does not offset the capital structure risk.
TRIP · Price
Company Overview
  • Company: Red Light Holland Corp. (CSE: TRIP, FSE: 4YX, OTCQB: TRUFF).
  • Flagship Project: PEX010, a botanical psilocybin drug candidate developed by subsidiary Filament Health.
  • Indications: Treatment-resistant depression, PTSD, cocaine use disorder, alcohol use disorder, cancer-related distress.
  • Regulatory Status: Phase 2 clinical trial authorization secured from FDA and Health Canada; supplied to over 70 global research sites.
  • Manufacturing: GMP-compliant facility acquired via Filament; Health Canada Level 8 Controlled Substances Dealer's Licence held.
Read the original news release →

More from Red Light Holland Corp.

Jun 18, 2026 · 09:02

Early-stage preclinical milestone adds to pipeline, but stock has already priced in a +200% run; execution risk remains high.

Other Jun 08, 2026 · 07:31

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Other Jun 04, 2026 · 07:32

Red Light Holland Secures UCSF Supply Deal for PEX010, But Clinical Progress Remains Incremental Amid Dilution Concerns

Other May 25, 2026 · 08:40

Red Light Holland Expands Filament Health Psychedelic Supply Footprint in New Zealand

Other May 14, 2026 · 08:31

Red Light Holland expands its clinical psilocybin network, but mounting share dilution and a transition to pharma leave investors waiting for a clear commercial catalyst.

Production / Operations May 13, 2026 · 09:13

Red Light Holland Consolidates Psychedelic Platform Post-Acquisition Amidst Management Transition

Financings